Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSJK6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,243
Award facts
- Contract value 100% obligated
- $11,242.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $11,242.98 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, on December 8, 2025. The delivery order, valued at approximately $11.2K, is for Dupixent 300 mg/2 ml pen injections and represents a continuation of DMS Pharmaceutical Group's critical role as a pharmaceutical supplier to the Department of Defense. This award carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The contract is funded entirely by the Defense Logistics Agency's Medical Supply Chain division, with performance completion scheduled for December 9, 2025.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded on November 13, 2025, with a $500M ceiling and completion date of December 31, 2036. The PPV-G GEN V represents a key component of the Department of Defense's broader pharmaceutical supply chain strategy, with DMS Pharmaceutical Group positioned as a regional prime vendor contractor serving military healthcare facilities worldwide. The contractor demonstrates substantial federal contracting experience across diverse pharmaceutical categories including specialty biologics, oncology treatments, vaccines, and routine medications, with no identified subcontractors on record.
Quick answers
Who was awarded contract SPE2DR26FSJK6?
SPE2DR26FSJK6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FSJK6 worth?
The government has obligated $11,243 on SPE2DR26FSJK6.
Is contract SPE2DR26FSJK6 an order under another contract?
Yes. SPE2DR26FSJK6 is a delivery order under SPE2DR25D9306, an indefinite delivery contract.
Was contract SPE2DR26FSJK6 competed?
The extent of competition for SPE2DR26FSJK6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award